Altamira Therapeutics Ltd
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses… Read more
Market Cap & Net Worth: Altamira Therapeutics Ltd (CYTO)
Altamira Therapeutics Ltd (NASDAQ:CYTO) has a market capitalization of $452.67K ($452.67K) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #38366 globally and #12482 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Altamira Therapeutics Ltd's stock price $0.12 by its total outstanding shares 3778520 (3.78 Million).
Altamira Therapeutics Ltd Market Cap History: 2015 to 2024
Altamira Therapeutics Ltd's market capitalization history from 2015 to 2024. Data shows change from $1.48 Trillion to $452.67K (-79.89% CAGR).
Altamira Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Altamira Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1199.27x
Altamira Therapeutics Ltd's market cap is 1199.27 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.48 Trillion | $-67.00K | -$29.70 Million | -22062040.62x | N/A |
| 2016 | $323.44 Billion | $-414.00K | -$30.66 Million | -781259.21x | N/A |
| 2017 | $178.50 Billion | $322.00K | -$24.41 Million | 554339.39x | N/A |
| 2018 | $13.78 Billion | $1.27 Million | -$11.50 Million | 10887.87x | N/A |
| 2019 | $2.45 Billion | $-56.00K | -$6.63 Million | -43722.87x | N/A |
| 2020 | $3.96 Billion | $174.47K | -$8.20 Million | 22696.02x | N/A |
| 2021 | $2.74 Billion | $63.88K | -$17.39 Million | 42941.76x | N/A |
| 2022 | $366.52 Million | $305.62K | -$26.53 Million | 1199.27x | N/A |
Competitor Companies of CYTO by Market Capitalization
Companies near Altamira Therapeutics Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Altamira Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Altamira Therapeutics Ltd Historical Marketcap From 2015 to 2024
Between 2015 and today, Altamira Therapeutics Ltd's market cap moved from $1.48 Trillion to $ 452.67K, with a yearly change of -79.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | $452.67K | -96.56% |
| 2023 | $13.15 Million | -96.41% |
| 2022 | $366.52 Million | -86.64% |
| 2021 | $2.74 Billion | -30.73% |
| 2020 | $3.96 Billion | +61.73% |
| 2019 | $2.45 Billion | -82.24% |
| 2018 | $13.78 Billion | -92.28% |
| 2017 | $178.50 Billion | -44.81% |
| 2016 | $323.44 Billion | -78.12% |
| 2015 | $1.48 Trillion | -- |
End of Day Market Cap According to Different Sources
On Dec 19th, 2025 the market cap of Altamira Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $452.67K USD |
| MoneyControl | $452.67K USD |
| MarketWatch | $452.67K USD |
| marketcap.company | $452.67K USD |
| Reuters | $452.67K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.